Boxer Capital’s Orchestra BioMed OBIO Stock Holding History

Boxer Capital’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-238,193	Closed	-$1.22M	–	36
2024 Q3	$1.22M	Hold	238,193	–	–	0.06%	62
2024 Q2	$1.94M	Hold	238,193	–	–	0.1%	53
2024 Q1	$1.26M	Hold	238,193	–	–	0.06%	54
2023 Q4	$2.17M	Hold	238,193	–	–	0.11%	41
2023 Q3	$2.08M	Sell	238,193 -11,807	-5%	-$79.4K	0.11%	57
2023 Q2	$1.75M	Hold	250,000	–	–	0.08%	69
2023 Q1	$4.89M	Hold	250,000	–	–	0.24%	50
2022 Q4	$2.5M	Sell	250,000 -150,000	-38%	-$1.49M	0.13%	57
2022 Q3	$3.96M	Hold	400,000	–	–	0.22%	58
2022 Q2	$3.98M	Hold	400,000	–	–	0.25%	59
2022 Q1	$3.96M	Hold	400,000	–	–	0.2%	61
2021 Q4	$4.03M	Hold	400,000	–	–	0.16%	61
2021 Q3	$3.96M	Hold	400,000	–	–	0.14%	77
2021 Q2	$4.08M	Hold	400,000	–	–	0.14%	81
2021 Q1	$4.48M	Hold	400,000	–	–	0.15%	73
2020 Q4	$5.12M	Hold	400,000	–	–	0.16%	68
2020 Q3	$4.4M	Buy	+400,000	New	+$4.49M	0.15%	67

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Boxer Capital's OBIO Position: Q4 2024 in Review

Boxer Capital sold out of Orchestra BioMed (OBIO) in Q4 2024, closing a stake of 238,193 shares — an estimated $1.22M sold.

Boxer Capital first reported a position in OBIO in Q3 2020 and held it in 17 quarters. The position peaked at $5.12M in Q4 2020. 54 funds tracked by Wall St. Rank hold OBIO as of Q4 2024.

Boxer Capital reported no remaining Orchestra BioMed position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 238,193 Orchestra BioMed shares in Q4 2024, an estimated $1.22M.
Boxer Capital first reported a position in Orchestra BioMed in Q3 2020 and held it in 17 quarters.
Boxer Capital's Orchestra BioMed position peaked at $5.12M in Q4 2020.
54 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.